Company Culture

Discussion in 'Alimera Sciences' started by anonymous, Mar 18, 2017 at 1:52 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    ONE TRICK PONY LIVING CHECK TO CHECK
    If you work at Alimera or are considering working hear you should run away as fast as you can! They are the only company in the Ophthalmology sector that has ZERO pipeline. They in licensed Iluvien for DME from another company (pSivida) and have no other products or indications on the horizon. There are no Phase 2 or phase 3 trials for additional indications in play. They have a Medical Affairs team but there is no real R & D team. Also, they missed every single forecast since launch and even if they begin to see an uptick in usage and make a little profit they will always be paying out licensing royalties to pSivida. The stock stays close to a dollar and will never jump much higher unless there is some solid improvement in revenue growth.
    So, if the company keeps missing forecast how long do you think the shareholders are going to listen to the same excuses. The company is operating at a loss every single quarter. Iluvien has been out for 3 years and has never had a good uptake with Retina. And if you look 2 years out or even 5 years out where will Alimera be? Other Ophthalmology companies are just watching and waiting for Alimera to crash so they can buy up any assets Alimera has (Iluvien) for cents on the dollar. Alimera should try to do what pSivida did when they bought Icon Bioscience and changed to EyePoint. That would be the only thing that could save them. But Alimera doesn't have the money and they don't develop their own medicines or technology. Alimera is not a real pharmaceutical company but instead a reseller of other companies technology. There is nothing to look forward to as there is no future without a pipeline.

    Don't get me wrong, Iluvien is a great product and its delivery system is really amazing.
    But, let's be real...Iluvien will never take off so Alimera will never take off!
     

  2. anonymous

    anonymous Guest

    NEW , now the uveitis approval didn´t com this year and the whole german medical team quits.
    the approval is set aside. the biggest thing the sales is 50% underperfomet. also in UK. protugal
    did also underperfomet. no need to desscribe the italien desaster.

    all people who work there , think to run away .
    the massivly limitations in marketing want bring the US sales in trouble.
    i pry for the last there , but it must get a wonder when tey got over Q3 in 2018 .

    run
     
  3. milo89

    milo89 New Member

    Joined:
    Apr 19, 2018
    Messages:
    1
    Likes Received:
    0
    best news for Newbies in german sales , the company must go for court for a trail
    with some employee , some for paimend some for somting else .
    crap
    perfect mangmtn , the way for wats VP,CEO stands for , OMG

    i think they want sell it , but who wants a white elephant .
    some one who buy some stock options have more than 20000 sell them for a penny
     
  4. anonymous

    anonymous Guest

    having just started I wish I read this thread before I started. So much truth here
    My boss appeared to be cool. He is a liar.
    Thinks he knows everything, knows nothing.
    Time to start looking
     
  5. anonymous

    anonymous Guest

    US lawsuit. Google it.
     
  6. anonymous

    anonymous Guest

    my boss just lies to me all day.
    Get me out of here
     
  7. anonymous

    anonymous Guest

  8. anonymous

    anonymous Guest

    Since January 16, 2018, it had 2 insider buys, and 10 sales for $280,303 activity. $12,742 worth of Alimera Sciences, Inc. (NASDAQ:ALIM) was sold by Green Kenneth. $65,294 worth of Alimera Sciences, Inc. (NASDAQ:ALIM) was sold by Myers C. Daniel on Tuesday, January 16. Shares for $22,800 were bought by ARMISTICE CAPITAL – LLC. Shares for $31,475 were sold by Ashman Philip on Tuesday, January 16. $30,552 worth of Alimera Sciences, Inc. (NASDAQ:ALIM) was sold by Holland David.
     
  9. anonymous

    anonymous Guest

    now the rats had an deal with valeant to sell the sinking ship!
    I think a rat is a rat . because alimera didn´t get an authorization for uveitis.

    and all rats are work-shy
    loss of over 400bil. $
     
  10. anonymous

    anonymous Guest

    I can't believe this business is still holding on. Valiant try when it started but could not build any depth of product.
     
  11. anonymous

    anonymous Guest

    Now they told the investors they won´t sell, Ricky Iceblock want earn mony, OMG who should believe this shit. They hade an new market-acess in spain with a price that was half of the price in germany. alimera get no profit. and with the last investor-news they wont throw sand in some
    piggy eye to slaughter them .
    no patient, no healing, no mony . OMG
     
  12. anonymous

    anonymous Guest

    Another 1, attempted, to Bite the Dust. MH interviewed with Sun Pharma, didn’t get the job!
     
  13. anonymous

    anonymous Guest

  14. anonymous

    anonymous Guest

     
  15. anonymous

    anonymous Guest

    It’s getting scary..... when ur VP of Sales, MH, is doing everything to get out.... interviewed with Shire too! It doesn’t make the team believe we have a chance to survive.
     
  16. anonymous

    anonymous Guest

    Interesting how he can’t get hired anywhere. Alimera people are soiling his name. Justified.
     
  17. anonymous

    anonymous Guest

    there are many trying to leave, including GC and HR, luckily everywhere each of those 2 have gone to interview, they were known and not hired. Eventual de-listing and bankruptcy to follow. Creditors, pSivida and loan writer will be knocking. Watch this space!
     
  18. anonymous

    anonymous Guest

    Whats going ohne with Mary.t.s. Now she had lost all of stock from sunfire. She had to do some wellfare work or she must have some psych Problem. As a new director she didn't had nowhere some place to hire.
    Omg whats wrong or the whana crap the last money out of the loan paymend ;-)